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Purpose: Intergroupe Francophone de Cance´rologie Thoracique-
0401 phase II trial aimed to evaluate the efficacy and safety of
gefitinib as a first-line treatment for patients with adenocarcinoma
with bronchioloalveolar carcinoma subtype (ADC-BAC).
Methods: Chemotherapy-naive patients (n  88) with advanced
ADC-BAC were treated with 250 mg/d of gefitinib. The primary
objective was assessment of disease control rate (DCR [objective
response  stable disease]) at 3 months using World Health Orga-
nization criteria. A disease control rate of 25% or greater would be
of interest in this patient population. Progression-free survival
(PFS), overall survival (OS), and toxicity were the secondary crite-
ria. Clinical and disease characteristics that conferred a favorable
prognosis under gefitinib were also analyzed.
Results: Disease control was achieved in 25 patients (29.4%); 11
patients (12.9%) had partial response and 14 (16.4%) had stable
disease. Median PFS was 2.9 months (95% confidence interval [CI],
2.3–3.2) and median OS was 13.2 months (95% CI, 10.2–17.3).
Never smokers, patients with low respiratory symptoms score,
occurrence of cutaneous rash, and nonmucinous ADC-BAC subtype
were associated with increased probability of disease control. Non-
mucinous ADC-BAC was associated with increased PFS and OS at
3 years. Patients with nonmucinous BAC had longer OS and PFS
compared with patients with other ADC-BAC variants; median PFS
for nonmucinous BAC was 11.3 months (95% CI, 3.2–14.7),
whereas it was 2.6 months (95% CI, 2.1–3) for mucinous BAC. As
expected, toxicity was low, with dermatological problems, diarrhea,
and nausea being the most common adverse events.
Conclusion: Results from the Intergroupe Francophone de Cance´r-
ologie Thoracique-0401 trial demonstrate that gefitinib combines
efficacy with low toxicity and is, therefore, suitable as a first-line
treatment of advanced ADC-BAC, particularly in patients with
nonmucinous BAC subtype.
Key Words: Bronchioloalveolar carcinoma, Mucinous cytologic
subtype, Nonmucinous cytologic subtype, Gefitinib.
(J Thorac Oncol. 2009;4: 1126–1135)
Bronchioloalveloar carcinoma (BAC) accounts for 3 to 4%of all cases of non-small cell lung carcinoma (NSCLC),
which is the primary cause of death by cancer in Europe and
the United States.1–3 BAC originates from terminal bronchio-
lar and acinar epithelia with no indication of stromal, vascu-
lar, or pleural intrusion and can be cytologically defined as
nonmucinous (the most common) or mucinous subtypes.4,5
More common than true BAC is the adenocarcinoma mixed
subtype with BAC (ADC-BAC), which has predominant BAC
features and invasive adenocarcinoma foci.4,6
ADC-BAC has distinct clinical and radiologic charac-
teristics because of disease progression in a lepidic and/or
aerogenous manner.5 Even with advanced disease at presen-
tation, nonpulmonary metastases are uncommon and recur-
rences are mainly in the ipsilateral or contralateral lung. BAC
and ADC-BAC have specific epidemiological features, in-
cluding no age and sex bias, and a predominance in patients
with a history of no smoking.3,5
Chemotherapy is widely perceived to be ineffective for
advanced BAC6 because low efficacy and high toxicity have
been limiting factors in pursuing paclitaxel treatment as an
attractive first-line therapy.6–8 Although less than 10% of
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unselected non-Asian patients with NSCLC respond to the
epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKI) erlotinib9 and gefitinib10 (ISEL, BR21), certain
population of patients are more susceptible to this therapy
including females, nonsmokers, Asians, and those with ADC-
BAC.11–13 A distinct molecular profile is thought to be re-
sponsible for increased sensitivity in these patients. Indeed,
EGFR polysomy14,15 and the presence of specific EGFR
mutations16,17 in tumor cells can both confer increased sen-
sitivity to EGFR-TKI therapy and are linked to EGFR-TKI-
sensitive populations.18
Despite promising evidence that gefitinib and erlotinib
are highly effective when targeted to receptive individu-
als,19,20 EGFR-TKIs are not yet approved as first-line treat-
ment for NSCLC and there is a need to further define those
patients who are most likely to respond to EGFR-TKI ther-
apy. This study was designed to elucidate the efficacy and
toxicity of gefitinib as a first-line treatment for advanced
BAC, ADC-BAC, or tumors that had cytologic features of
BAC when no histologic specimen was available. The demo-
graphic and clinical factors that act as markers of sensitivity
to EGFR-TKI treatment were also explored.
PATIENTS AND METHODS
Eligibility
Patients had histologically proven advanced ADC-
BAC (stage IIIB/IV) or recurrent disease at the time of trial
inclusion; inoperable patients with less than IIIB/IV stage
disease were also eligible. Patients with cytologic features of
BAC but without available histologic specimens were eligi-
ble, if they had a diffuse or pneumonic-type radiologic
presentation suggestive of ADC-BAC.21 Initial ADC-BAC
diagnosis was based on institutional pathologic assessment, and
specimens were subsequently reviewed by the Bio-Intergroupe
Francophone de Cance´rologie Thoracique (IFCT)-0401 patho-
logic panel.
Patients older than or equal to 18 years and with an
Eastern Cooperative Oncology Group performance status
(PS) of 0, 1, 2, or 3 were eligible. Within 1 month of study
inclusion, all patients were to have evidence of pulmonary
lesion on computed tomography (CT) of the chest and a
normal fiberoptic bronchoscopy. Lesions were assessed by
the World Health Organization (WHO) criteria.22 Extratho-
racic work-up consisted of CT or magnetic resonance imag-
ing of the brain and upper abdominal CT or ultrasonography.
Other investigations were performed depending on clinical
symptoms. No previous systemic therapy for ADC-BAC was
allowed. Previous radiation was allowed if disease was present
outside the radiation port and previous surgery was also allowed.
All patients were informed of the investigational nature
of this study and gave a written informed consent before
inclusion. The study was performed in accordance with local
institutional review board regulations, national guidelines,
and good clinical practices.
Study Design
Gefitinib was administered orally at a dose of 250
mg/d. Treatment continued until disease progression or lim-
iting toxicity. Toxicities were graded according to the Na-
tional Cancer Institute Common Toxicity Criteria Version
2.0. Treatment was temporarily withdrawn for up to 2 weeks
in case of grade 3 or 4 toxicity; no dose reduction was
permitted. Treatment was restarted on improvement of tox-
icity to less than or equal to grade 2. Patients who were
unable to restart treatment after 2 weeks, or who required a
second gefitinib withdrawal, were removed from the study.
Age, sex, smoking status, and history of previous treat-
ment by surgery or radiotherapy were recorded at inclusion.
Information was also collected regarding tumor, node, me-
tastasis staging at initial diagnosis, BAC cytologic subtypes
(nonmucinous or mucinous), and sites of metastatic involve-
ment (either extrathoracic or separate thoracic lesions in other
lobes). Other data collected at the time of inclusion and
before each month were the presence of bronchorrhea (spu-
tum production 100 mL/d), the rales on thoracic ausculta-
tion, the presence of oxygen saturation (SaO2) less than 95%
by pulse digital oxymetry, and the need for oxygen support.
Quality of life was evaluated by a respiratory symptoms score
(RSS) adapted from the study of Teeter and Bleecker23 at
inclusion, month 1, month 3, and then every 3 months. For
RSS, patients rated each symptom (cough, dyspnea, wheeze,
chest tightness, sputum production, and nocturnal awakening)
on a six-point scale ranging from 0 (no symptoms) to 4 (con-
stant). One missing point invalidated the whole questionnaire.
Overall function scores (0–24) were calculated, with lower
scores reflecting better function and symptom response.
Study Evaluation
Response assessments (complete or partial response or
stable disease) were evaluated by CT using WHO criteria
after 3 months, then every 3 months. Objective response was
to be confirmed after 4 weeks by a second CT. Disease
progression occurring before the end of the third month was
to be established by CT, whenever possible. All responses
were centrally reviewed by the IFCT-0401 clinical panel.
For patients removed from gefitinib for disease progres-
sion or unacceptable toxicity and still eligible for chemother-
apy, treatment regimens of carboplatin plus paclitaxel (PS 0
or 1) or gemcitabine monotherapy (PS 2) were recommended,
although they were not mandatory. Patients no longer receiv-
ing treatment were followed up every 3 months until death,
by clinical and CT evaluation. Progression-free survival
(PFS) on gefitinib and overall survival (OS) were calculated
from the date of inclusion in the study.
Statistical Methods
Because adequate radiologic methods to measure ob-
jective response in patients with advanced BAC are lacking,
the IFCT-0401 trial scientific committee decided to make
disease control rate (DCR; [objective response  stable
disease]) at 3 months the primary objective of the study.
Moreover, because evaluation by RECIST tends to delay the
diagnosis of disease progression24,25 compared with evalua-
tion by WHO criteria, it seemed more relevant to evaluate
disease control by WHO criteria in this study. Secondary
objectives were the evaluation of toxicity, PFS and OS, and
change in quality of life in the overall eligible population.
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A DCR of 25% or greater would be of interest in this
patient population. If more than or equal to 1 response was
noted in the first 14 patients, an additional 66 patients were to
be enrolled. With an expected DCR of 25% and the inclusion
of 80 patients, the precision obtained was nine points, i.e., a
95% confidence interval (CI; 16%–34%). The planned sam-
ple size was increased to 90 assessable patients to allow
exploratory analyses of clinically predefined patient subsets
and to provide additional pathologic material for the subse-
quent Bio-IFCT-0401 trial.
Differences in proportions were analyzed by 2 test or
Fisher’s exact test when necessary. A stepwise logistic re-
gression analysis26 was conducted to explore demographic
and clinical factors associated with disease control and re-
sponse. Adequacy of the model was assessed using the
Hosmer and Lemeshow goodness-of-fit test; a high p value
will confirm the interest of the model. OS and PFS were
estimated using the Kaplan-Meier method.27 Median survival
time was estimated as described by Brookmeyer and Crow-
ley.28 For OS and PFS, a Cox model29 was used to calculate
the hazard ratio (HR) and Wald 2 test for each variable.
Stepwise Cox models were then used to identify factors
significantly associated with survival. Values of p  0.05
were considered statistically significant. All analyses were
carried out using SAS software, version 9.1 (SAS Institute
Inc., Cary, NC).
RESULTS
Patient Characteristics
The enrollment period was April 2004 to July 2005,
and the date of end point was June 30, 2008. Ninety patients
were registered and 88 were eligible (Table 1). Median age
was 64 years (range: 27–83) and one third of the patients
were older than 70 years old. At the time of inclusion, all but
two patients had advanced disease (97.7%) and two patients
had unilateral lung disease but inadequate pulmonary func-
tion tests for surgical resection. Eighty patients had bilateral
pulmonary disease (58 at initial diagnosis and 22 in relapse
after surgery) and six had unilateral disease but extrathoracic
metastases.
Forty-four patients (50%) had rales at thoracic auscul-
tation and six had bronchorrhea; 39 patients (48%) had SaO2
less than 95% of which two thirds needed oxygen-support: 23
(26%) had a diffuse or pneumonic-type radiologic presenta-
tion. A high RSS (median: 9, range: 0–24) was associated
with the presence of rales (p  0.0001), bronchorrhea (p 
0.033), SaO2 less than 95% (p  0.0004), and diffuse or
pneumonic-type radiologic presentation (p  0.001).
According to the 2004 WHO pathologic classification,
patients were distributed in five categories adapted from West
et al.31: 43.2% had a mucinous BAC, 23.9% had a nonmu-
cinous BAC, 6.8% had a BAC that was cytologically unspec-
ified, and 9.1% had a non-BAC-ADC (all of the papillary
subtype; Table 1). Finally, 17% had an ADC-BAC diagnosed
on cytologic specimens only32; interestingly, they only dif-
fered from the other ADC-BAC categories with a more
frequently diffuse or pneumonic-type radiologic presentation
(60% versus 19.2%, p  0.002).
Disease Control and Response by Patient
Subset
Eighty-five of the 88 eligible patients were assessed for
response at 3 months (two deaths not related to lung cancer
before 3 months and one premature study discontinuation).
Disease control at 3 months was achieved in 25 patients
(29.4%); 11 patients had partial response (12.9%) and 14
patients had stable disease (16.4%; Table 2).
Patient subsets of never smoking, low RSS, or nonmu-
cinous BAC cytology (OR  1, for mucinous) had a signif-
icantly increased probability of disease control at 3 months
(univariate and multivariate analyses, Table 3). Development
of cutaneous rash during the treatment was also associated
with a higher DCR. Objective response at 3 months was not
observed in male patients (p  0.002) or in patients who did
not develop a rash (p  0.059; Table 3). The small sample
size restricted performance of multivariate analysis on objec-
tive response data.
Overall and Progression-Free Survivals
The median duration of follow-up was 13 months
(range: 11 days–58 months). No patient was lost to follow-up.
Forty-six patients (52.3%) received a second line of chemo-
therapy or further line of chemotherapy (see Discussion
section). Sixty-five patients died during the study; however,
none of these deaths were attributed to gefitinib toxicity.
Median PFS was 2.9 months (Table 2, Figure 1A) and median
TABLE 1. Characteristics of 88 Eligible Patients at Inclusion
Characteristics n (%)
Age (yr)
70 56 (63.6)
70 32 (36.4)
Sex
Female 48 (54.5)
Male 40 (45.5)
Smoking status
Current/former 50 (56.8)
Never smoked 38 (43.2)
Performance status
0, 1 72 (81.8)
2 16 (18.2)
Respiratory symptoms score (RSS)a
9 37 (43.5)
9 48 (56.5)
Initial TNM staging
Stages I–IIIA 15 (17)
Stages IIIB–IV 73 (83)
Pathological characteristics
BAC, mucinous 38 (43.2)
BAC, nonmucinous 21 (23.9)
BAC, cytologically unspecified 6 (6.8)
BAC, diagnosed by cytology 15 (17.0)
ADC non-BAC 8 (9.1)
a The cutoff value of 9 was the median of the distribution of the RSS in the study
population.
ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma.
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OS was 13.2 months (Table 2, Figure 1B), with a 1-year,
2-year, and 3-year survival rates of 54.4, 29.5, and 20.2%,
respectively (Table 2).
Progression-Free Survival by Patient Subset
Table 4 shows factors associated with a significant
HR for increased PFS with gefitinib. A significantly im-
proved probability of PFS at 3 years with gefitinib was
associated with the factors of lower RSS at inclusion,
nonmucinous cytologic type of BAC, rash during treat-
ment, and to a lesser extent of age more than 70 years. PFS
at 3 years was significantly more probable for patients with
nonmucinous BAC (HR of 0.41) than for those with
mucinous BAC (Table 4).
Median PFS for patients with nonmucinous BAC his-
tology was 11.3 months (95% CI, 3.2–14.7), significantly
longer than for mucinous BAC (2.6 months; 95% CI, 2.1–3.0;
Figure 1C), non-BAC-ADC (3.2 months; 95% CI, 2.0–15.1),
cytologically unspecified BAC (3.4 months; 95% CI, 1.2–
25.3), and ADC-BAC diagnosed on cytologic specimens (2.2
months; 95% CI, 1.9–2.8), p  0.002.
A significantly longer median PFS was observed for
patients with an RSS less than 9 at inclusion (3.4 months;
95% CI, 3.0–10.6), compared with those with RSS more than
or equal to 9 (2.1 months; 95% CI, 2.0–2.8), p 0.0006, and
also for patients who developed a rash (3.0 months; 95% CI,
2.7–3.7), compared with those who did not (1.9 months; 95%
CI, 1.4–3.2), p  0.0001.
TABLE 2. Clinical Efficacy and Survival
Condition n (%) 95% CI
Overall response
Complete response 0 (0) —
Partial response 11 (12.9) 6–20
Stable disease 14 (16.4) 9–24
Controlled disease 25 (29.4) 20–39
Progressive disease 60 (70.6) 61–80
Progression-free survival (PFS)a
Median 2.9 mo 2.4–3.2
1-yr PFS 20.5% 12.6–29.7
2-yr PFS 12.2% 6.2–20.5
Overall survival (OS)a
Median 13.2 mo 10.1–17.3
1-yr OSa 54.4% 43.4–64.1
2-yr OSa 29.1% 19.8–39.1
a Median survival, 1- and 2-yr survival and progression-free survival were deter-
mined on the 88 patients included in the study whereas response was determined on the
85 assessable patients.
CI, confidence interval.
TABLE 3. Characteristics Associated with Disease Control and Objective Response at 12 wk on the 85 Evaluated Patients
(Univariate and Multivariate Analyses)
Characteristic
Univariate Analysis Multivariate Analysisa
DC Rates
(%)
Odds
Ratio 95% CI p
OR Rates
(%)
Odds
Ratio 95% CI p
Odds
Ratio 95% CI p
Age
70 yr 23.6 1 — — 7.3 1 — — 1 — —
70 yr 40.0 2.15 0.82–5.62 0.117 23.3 3.88 1.03–14.58 0.045 3.74 0.92–15.18 0.065
Sex
Male 18.9 1 — — 0.0 1 — — — — —
Female 37.5 2.57 0.94–7.05 0.067 22.9 UD
Smoking status
Current/former 19.1 1 — — 2.1 1 1 — —
Never smoker 42.1 3.07 1.16–8.11 0.024 26.3 16.43 1.99–35.32 0.009 5.78 1.34–24.96 0.019
RSSb
9 17.4 1 — — 8.7 1 1 — —
9 44.4 3.80 1.39–10.40 0.009 16.7 2.10 0.54–8.09 0.281 7.24 1.82–28.79 0.005
Histology
BAC-cytologyc 15.4 0.97 0.17–5.53 0.972 7.7 0.97 0.09–10.26 0.981 1.84 0.23–14.76 0.565
BAC, m 15.8 1 — — 7.9 1 — — 1 — —
ADC non-BAC 25.0 1.78 0.29–11.00 0.536 12.5 1.67 0.15–18.45 0.677 13.31 1.18–149.83 0.036
BACd 33.3 2.67 0.39–17.98 0.314 0.0 UD — — 3.35 0.39–28.89 0.271
BAC, nm 65.0 9.90 2.79–35.15 0.000 30.0 5.00 1.10–22.82 0.038 13.52 2.34–78.20 0.004
Cutaneous rash
No 9.1 1 — — 0.0 UD — — 1 — —
Yes 36.5 5.75 1.23–26.86 0.026 17.5 1 7.43 1.12–49.40 0.038
a Stepwise regression using p  0.2 and p  0.1, as entry and stay threshold levels. Goodness-of-fit test indicates that the model performed well (p  0.092).
b Respiratory symptoms score (RSS) was defined in Material and Method section; the cutoff value of 9 was the median of the distribution of the RSS in the study population.
c BAC diagnosed by cytology.
d BAC, cytologically unspecified.
ADC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; m, mucinous; nm, nonmucinous; UD, undeterminable as no event in one class for the evaluated characteristic; DC,
disease control; OR, objective response; 95% CI, 95% confidence interval; p, p value by 2 test.
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Overall Survival by Patient Subset
Factors associated with a significant HR for increased
OS are displayed in Table 5. A significantly increased prob-
ability of 3-year survival was associated with RSS less than
9 at inclusion, nonmucinous cytologic type of BAC, and
presence of rash during treatment.
Median OS for nonmucinous BAC was 32.7 months
(95% CI, 18.2 to undeterminable) and was significantly
longer compared with cytologically unspecified BAC (19.6
months; 95% CI, 7.7–31.5), non-BAC-ADC (19.6 months;
95% CI, 13.9–35.9), mucinous BAC (10.1 months; 95% CI,
8.4–13.4; Figure 1D), and ADC-BAC diagnosed on cytologic
specimens (5.3 months; 95% CI, 2.7–12.1), p  0.0007.
Median OS was 23.9 months (95% CI, 12.1 to unde-
terminable) for patients with RSS less than 9 at inclusion and
significantly longer than for patients with RSS scores more
than or equal to 9 (9.4 months; 95% CI, 4.5–13.9), p 
0.0001. Median OS was 15.1 months (95% CI, 11.7–25.0) for
patients who developed a rash with gefitinib treatment and
significantly longer than for patients who did not (6.8 months;
95% CI, 1.9–12.6), p  0.0002.
Toxicity
Dermatological problems were the most commonly
reported adverse events (85.2% of patients), among which
rash and/or acne were the most frequent manifestations ob-
FIGURE 1. Progression-free survival (PFS) and overall survival (OS) among IFCT-0401 trial population. Panel A, PFS for all pa-
tients; Panel B, OS for all patients. Panel C, PFS divided into patients with nonmucinous (blue line) and mucinous BAC (red
line). Panel D, OS divided into patients with nonmucinous (blue line) and mucinous bronchioloalveloar carcinoma (BAC; red
line). Dotted lines represent 95% confidence interval (CI).
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served (59.1% of patients, Table 6). The severity of derma-
tological events was graded 3 and 4 in 4.6% of cases.
Diarrhea (less than grade 3) occurred in 43.2% of the pa-
tients; however, digestive toxicity caused drug withdrawal in
only one patient (who developed grade 4 mucositis and other
skin problems at month 4). Asthenia and elevated transami-
nases were less common. Only one patient experienced dys-
pnea (grade 3) as a serious adverse event on day 49. Dyspnea
rapidly improved after gefitinib withdrawal, and the patient
was still alive under chemotherapy at month 18.
DISCUSSION
The IFCT-0401 trial confirmed that gefitinib (250 mg)
was effective in the treatment of chemotherapy-naive patients
with advanced ADC-BAC. A DCR of 29.4%, median PFS of
2.9 months, and median OS of 13.2 months were achieved in
this unselected population of patients. Moreover, results from
this trial suggest that EGFR-TKIs may benefit patients with
cytologically nonmucinous BAC, but not mucinous BAC.
Therefore, including patients with cytologic diagnosis of
ADC-BAC did not alter the conclusions of this study. It is
clear that histology rather than cytology is desirable for the
diagnosis of advanced BAC. However, cytology diagnosis for
BAC was highly specific (99%) despite being nonsensitive
(12%)31 and was only considered adequate enough for the
diagnosis of ADC-BAC in our trial of patients with pneumo-
nic-type or diffuse radiologic presentation and normal fiber-
optic bronchoscopy.21
Two earlier phase II EGFR-TKIs trials have achieved
similar results.30,32 The earlier trial evaluated gefitinib (500
mg/d) in 101 previously untreated patients with advanced
BAC, and reported as a primary objective, a median OS of 13
months30; the median PFS was 4 months and the median
DCR was 49% in 69 patients evaluated. The later trial tested
erlotinib (150 mg/d) in first-line treatment of 75 patients with
ADC-BAC and showed as primary objective a 22% response
rate at 8 weeks32; the median PFS was 4 months and OS was
17 months. Divergences in results among all the three studies
TABLE 4. Characteristics Associated with Progression-Free Survival at 3 yr (Univariate
and Multivariate Cox’s Model Analysesa)
Characteristic
Univariate Analysis Multivariate Analysis
HR 95% CI p HR 95% CI p
Age
70 yr 1 — 1 —
70 yr 0.73 0.45–1.20 0.214 0.57 0.33–0.98 0.043
Sex
Male 1 — — — —
Female 0.85 0.54–1.35 0.505
Smoking status
Current/former 1 — — — —
Never smoker 0.80 0.51–1.27 0.348
Initial TNM staging
IIIB–IV 1 — — — —
I–IIIA 0.82 0.45–1.50 0.523
PS
2 1 — — — —
0,1 0.87 0.49–1.56 0.645
RSSb
9 1 1
9 0.46 0.29–0.75 0.002 0.34 0.20–0.59 0.0001
Histology
ADC-cytologyc 1.41 0.74–2.69 0.297 0.93 0.47–1.84 0.835
ADC-BAC, m 1 1
ADC non-BAC 0.75 0.34–1.62 0.461 0.33 0.13–0.84 0.020
BACd 0.43 0.15–1.23 0.119 0.38 0.13–1.11 0.078
ADC-BAC, nm 0.35 0.18–0.66 0.001 0.36 0.18–0.71 0.003
Cutaneous rash
No 1 1
Yes 0.44 0.26–0.74 0.002 0.42 0.24–0.74 0.002
a Stepwise regression using p  0.2 and p  0.1 as entry and stay threshold levels.
b Respiratory symptoms score (RSS) was defined in Material and Method section; the cutoff value of 9 was the median
of the distribution of the RSS in the study population.
c BAC diagnosed by cytology.
d BAC, cytologically unspecified.
HR, hazard ratio; CI, confidence interval; p, p value by 2 test; PS, performance status; ADC, adenocarcinoma; BAC,
bronchioloalveolar carcinoma; m, mucinous; nm, nonmucinous.
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may be due to the different primary objectives (DCR at 12
weeks, OS at 1 year,30 and response rate at 8 weeks32) and the
different frequency (every 12 versus every 8 weeks30,32) and
method (WHO versus RECIST30,32) of evaluation, which
could affect DCR and PFS.24,25 Dosage was also higher in the
earlier gefitinib trial (250 mg versus 500 mg30); however,
higher gefitinib dose did not result in increased efficacy in
previous trials.34,35 Erlotinib improved survival and gefitinib
did not in trials of unselected patients with NSCLC.9,10
However, a direct comparison of results is difficult as erlo-
tinib was used at the maximally tolerated dose (MTD, 150
mg/d), whereas gefitinib dosage was below MTD (MTD, 600
mg/d).36 Importantly, all EGFR-TKI trial data on general
populations are influenced by the proportion of patient sub-
groups with varying sensitivity to EGFR-TKI; the proportion
of females, never smokers, Asians, and nonmucinous BAC
(see later) will have a great impact on the response and
consequently on the PFS.37
Gefitinib was relatively well tolerated with low toxicity
and adverse events comparable with other EGFR-TKI tri-
als.28,29 Incidence of grade 3 or 4 toxicity was low (9.0%). No
patient died of treatment-related events, and only two
patients discontinued gefitinib prematurely because of ad-
verse dermatological and respiratory events. These results
are far better than those reported for previous chemother-
apy trials with paclitaxel infusion.7,8 Lower toxicity levels
and equivalent survival rates suggest that EGFR-TKI ther-
apy is a favorable choice for first-line treatment of ad-
vanced BAC.
This study confirmed that never smokers, females, and
patients who develop a rash during treatment respond well to
EGFR-TKI, whereas age had only a minor impact. A higher
RSS strongly correlated with clinical (rales and bronchor-
rhea) and radiologic (diffuse or pneumonic type) character-
istics that were associated with poor prognosis in ADC-BAC
in a previous report.21 A low RSS also independently pre-
TABLE 5. Characteristics Associated with 3-yr Survival (Univariate and Multivariate
Cox’s Model Analysesa)
Characteristic
Univariate Analysis Multivariate Analysis
HR 95% CI p HR 95% CI p
Age
70 yr 1 — — —
70 yr 0.69 0.41–1.16 0.162
Sex
Male 1 — — —
Female 0.96 0.58–1.59 0.872
Smoking status
Current/former 1 — — —
Never smoker 0.95 0.57–1.57 0.834
Initial TNM staging
IIIB–IV 1 1
I–IIIA 0.48 0.23–1.00 0.051 0.37 0.17–0.83 0.016
PS
2 1 — — NS
0, 1 0.41 0.22–0.74 0.003
RSSb
9 1 1
9 0.44 0.25–0.76 0.003 0.35 0.20–0.63 0.0004
Histology
ADC-cytologyc 1.45 0.76–2.78 0.263 0.88 0.44–1.74 0.709
BAC, m 1 1
ADC non-BAC 0.49 0.19–1.27 0.145 0.15 0.04–0.51 0.002
BACd 0.45 0.14–1.47 0.184 0.16 0.05–0.54 0.003
BAC, nm 0.35 0.17–0.74 0.006 0.33 0.15–0.74 0.007
Cutaneous rash
No 1 1
Yes 0.39 0.23–0.66 0.0004 0.30 0.17–0.54 0.0001
a Stepwise regression using p  0.2 and p  0.05 as entry and stay threshold levels.
b Respiratory symptoms score (RSS) was defined in Material and Method section; the cutoff value of 9 was the median
of the distribution of the RSS in the study population.
c BAC diagnosed by cytology.
d BAC cytologically unspecified.
HR, hazard ratio; CI, confidence interval; p, p value by 2 test; PS, performance status; ADC, adenocarcinoma; BAC,
bronchioloalveolar carcinoma; m, mucinous; nm, nonmucinous.
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dicted improved DCR, PFS, and OS, and a decrease in RSS
at 4 weeks was associated with disease control at 12 weeks
(data not shown).38 These findings suggest that RSS may be
a good clinical surrogate marker of efficacy in trials evaluat-
ing ADC-BAC, a tumor for which CT-scan assessment is
often difficult.39
Importantly, patients with nonmucinous BAC had sig-
nificantly improved DCR and PFS under gefitinib, whereas
patients with mucinous BAC did not. This improvement also
had an impact on OS and was independent of other predictive
criteria such as smoking, female gender, and rash; the pro-
portion of patients with these characteristics did not differ
between mucinous and nonmucinous subgroups (data not
shown). The Kaplan-Meier curve of overall PFS is biphasic
(Figure 1A; a feature also observed in the two earlier trials
using EGFR-TKI28,29), suggesting that the global popula-
tion consists of two biologically distinct populations with
differing sensitivity to gefitinib: one population does not
respond well to gefitinib and has a low probability of PFS
during the first 4 months (causing a steep curve gradient)
and one population responds well to gefitinib and has a
longer PFS duration (depicted by a shallow curve gradient
in later months). Curves for PFS in nonmucinous BAC and
mucinous BAC subgroups diverge at approximately 4
months, which could suggest that these two patient subsets
represent the two distinctly responding biologic popula-
tions (Figure 1C).
Nonmucinous BAC arises from terminal respiratory
unit (TRU) cells comprised of Clara cells and type II pneu-
mocytes, whereas mucinous BAC derives from a mucinous
metaplasia of the bronchiolar epithelium. Development of
TRU-derived nonmucinous BAC is associated with HER2
gene expression,12,40 high rates of EGFR polysomy or muta-
tion,18,41,42 and sustained expression of the transcription fac-
tor TTF1.43,44 Conversely, non-TRU-derived mucinous
BAC is little dependent on EGFR and is in part driven by
altered K-ras signaling pathways and K-ras muta-
tions.41,42,44 Patients with BAC with increased EGFR poly-
somy or expression of somatic EGFR mutations are more
sensitive to EGFR-TKI therapy, but K-ras mutations are
found more frequently in patients not sensitive to EGFR-
TKI.15,29,45 Consistent with this, nonmucinous BAC re-
sponds favorably to gefitinib therapy, whereas mucinous
features exert a negative effect on the survival of patients
under this treatment.15 It, therefore, seems likely that the
two BAC populations with different response to gefitinib
in this study also differ in EGFR and/or K-ras signaling at
the molecular level, and may represent two separate dis-
ease phenotypes.46
Despite the presence of two distinct populations with
regard to gefitinib response, the global population OS
Kaplan-Meier curve is monophasic (Figure 1B), and nonmu-
cinous versus mucinous BAC subgroup OS curves do not
diverge until 22 months (Figure 1D). This suggests that there
are a certain number of mucinous patients with disease
progression under gefitinib who benefit from chemotherapy
and thus have improved OS. In this trial, a second or further
line of chemotherapy was offered to 46 patients who
progressed on gefitinib, including taxan-based chemother-
apy (n  30) and gemcitabine (n  24). Among them,
18/30 were controlled by taxans and 5/24 by gemcitabine
(manuscript in preparation). Moreover, paclitaxel may be
suggested to have increased efficacy in mucinous or mixed
BAC,8 and pemetrexed has achieved a partial response
after progression in patients with advanced BAC previ-
ously treated by EGFR-TKI and paclitaxel.47 It is conceiv-
able that paclitaxel, EGFR-TKI, and pemetrexed preferen-
tially target different patient populations with BAC, which
could form the basis of an effective therapy against BAC.
This issue is currently under investigation in the IFCT-
0504 trial.31
In conclusion, the outcome of this trial supports the
argument that EGFR-TKI therapy combines efficacy with
low toxicity and is, therefore, suitable as a first-line treatment
of advanced ADC-BAC, particularly in patients with nonmu-
cinous BAC histology. Our findings also suggest that future
trials on advanced BAC will have to better individualize
cytologic subtypes—nonmucinous and mucinous—and their
molecular characteristics in an intent to improve decision
making in the treatment of this challenging population of
patients.
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